Market Overview

Canaccord Genuity Maintains Hold on Cardiome Pharma Corporation, Raises PT to $0.40

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CRME

DateFirmActionFromTo
Nov 2017Canaccord GenuityMaintainsBuy
Jul 2017Canaccord GenuityAssumesBuy
Dec 2016Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for CRME
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (CRME)